Jones-Freeman Bernadette, Chonwerawong Michelle, Marcelino Vanessa R, Deshpande Aniruddh V, Forster Samuel C, Starkey Malcolm R
Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Mucosal Immunol. 2021 Jul;14(4):779-792. doi: 10.1038/s41385-020-00372-5. Epub 2021 Feb 4.
The urinary tract consists of the bladder, ureters, and kidneys, and is an essential organ system for filtration and excretion of waste products and maintaining systemic homeostasis. In this capacity, the urinary tract is impacted by its interactions with other mucosal sites, including the genitourinary and gastrointestinal systems. Each of these sites harbors diverse ecosystems of microbes termed the microbiota, that regulates complex interactions with the local and systemic immune system. It remains unclear whether changes in the microbiota and associated metabolites may be a consequence or a driver of urinary tract diseases. Here, we review the current literature, investigating the impact of the microbiota on the urinary tract in homeostasis and disease including urinary stones, acute kidney injury, chronic kidney disease, and urinary tract infection. We propose new avenues for exploration of the urinary microbiome using emerging technology and discuss the potential of microbiome-based medicine for urinary tract conditions.
泌尿系统由膀胱、输尿管和肾脏组成,是过滤和排泄废物以及维持全身稳态的重要器官系统。在此功能中,泌尿系统会受到其与其他黏膜部位相互作用的影响,包括泌尿生殖系统和胃肠道系统。这些部位中的每一个都拥有被称为微生物群的多样微生物生态系统,该生态系统调节与局部和全身免疫系统的复杂相互作用。目前尚不清楚微生物群及其相关代谢产物的变化是泌尿系统疾病的结果还是驱动因素。在这里,我们综述当前文献,研究微生物群在稳态和疾病状态下对泌尿系统的影响,包括尿路结石、急性肾损伤、慢性肾病和尿路感染。我们提出利用新兴技术探索泌尿微生物组的新途径,并讨论基于微生物组的医学对泌尿系统疾病的治疗潜力。